Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cumulative risk of developing a new symptom in patients with primary biliary cholangitis and its impact on prognosis.
Kimura N, Setsu T, Arao Y, Sakai N, Watanabe Y, Abe H, Kamimura H, Sakamaki A, Yokoo T, Kamimura K, Tsuchiya A, Osaki A, Igarashi K, Waguri N, Yanagi M, Takahashi T, Sugitani S, Kobayashi Y, Takamura M, Yoshikawa A, Ishikawa T, Yoshida T, Watanabe T, Bannai H, Kubota T, Funakoshi K, Wakabayashi H, Kurita S, Ogata N, Watanabe M, Mita Y, Mori S, Sugiyama M, Miyajima T, Takahashi S, Sato S, Ishizuka K, Ohta H, Aoyagi Y, Terai S. Kimura N, et al. Among authors: watanabe t, watanabe y, watanabe m. JGH Open. 2022 Jul 15;6(8):577-586. doi: 10.1002/jgh3.12789. eCollection 2022 Aug. JGH Open. 2022. PMID: 35928695 Free PMC article.
Changes in disease characteristics of primary biliary cholangitis: An observational retrospective study from 1982 to 2016.
Takamura M, Matsuda Y, Kimura N, Takatsuna M, Setsu T, Tsuchiya A, Osaki A, Waguri N, Yanagi M, Takahashi T, Sugitani S, Kobayashi Y, Yoshikawa A, Ishikawa T, Yoshida T, Watanabe T, Bannai H, Kubota T, Funakoshi K, Wakabayashi H, Kurita S, Ogata N, Watanabe M, Mita Y, Mori S, Sugiyama M, Miyajima T, Takahashi S, Sato S, Ishizuka K, Ohta H, Aoyagi Y, Terai S; Niigata PBC Study Group. Takamura M, et al. Among authors: watanabe t, watanabe m. Hepatol Res. 2021 Feb;51(2):166-175. doi: 10.1111/hepr.13586. Epub 2020 Nov 28. Hepatol Res. 2021. PMID: 33126288
Absence of pretreatment markers that predict the emergence of YMDD mutants during lamivudine treatment--the results of a prospective multi-center study.
Yano M, Ohkoshi S, Suzuki K, Ito S, Wakabayashi H, Sugiyama M, Watanabe T, Maeda H, Hatakeyama SA, Hatano T, Kobayashi Y, Takei S, Kohjiro H, Tsuboi Y, Takahashi T, Ishikawa T, Kamimura T, Ichida T, Aoyagi Y. Yano M, et al. Among authors: watanabe t. Hepatogastroenterology. 2006 Jan-Feb;53(67):124-7. Hepatogastroenterology. 2006. PMID: 16506390
Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C.
Aoki YH, Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Waguri N, Igarashi K, Sugitani S, Takahashi T, Ishikawa T, Kamimura T, Wakabayashi H, Watanabe T, Matsuda Y, Nomoto M, Aoyagi Y. Aoki YH, et al. Among authors: watanabe t. Hepatol Res. 2011 Feb;41(2):118-25. doi: 10.1111/j.1872-034X.2010.00749.x. Hepatol Res. 2011. PMID: 21269381
Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy.
Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Waguri N, Igarashi K, Sugitani S, Takahashi T, Ishikawa T, Kamimura T, Wakabayashi H, Watanabe T, Matsuda Y, Aoyagi Y. Ohkoshi S, et al. Among authors: watanabe t. Hepatogastroenterology. 2011 May-Jun;58(107-108):965-70. Hepatogastroenterology. 2011. PMID: 21830425
Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.
Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H, Naito A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T. Takimoto M, et al. Among authors: watanabe t. Dig Dis Sci. 2002 Jan;47(1):170-6. doi: 10.1023/a:1013244326874. Dig Dis Sci. 2002. PMID: 11837720
Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis.
Suzuki K, Ohkoshi S, Yano M, Ichida T, Takimoto M, Naitoh A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T, Aoyagi Y. Suzuki K, et al. Among authors: watanabe t. Liver Int. 2003 Jun;23(3):143-7. doi: 10.1034/j.1600-0676.2003.00822.x. Liver Int. 2003. PMID: 12955876
Hematologic malignancies in the Japanese patients with inflammatory bowel disease.
Fukata N, Okazaki K, Omiya M, Matsushita M, Watanabe M; Members of the Ministry of Health and Welfare of Japan’s Inflammatory Bowel Diseases Study Group. Fukata N, et al. J Gastroenterol. 2014 Sep;49(9):1299-306. doi: 10.1007/s00535-013-0873-3. Epub 2013 Aug 19. J Gastroenterol. 2014. PMID: 23955181
15,902 results
You have reached the last available page of results. Please see the User Guide for more information.